Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1991 1
1992 32
1993 135
1994 167
1995 146
1996 169
1997 214
1998 189
1999 251
2000 241
2001 267
2002 279
2003 334
2004 332
2005 427
2006 446
2007 566
2008 628
2009 713
2010 819
2011 978
2012 1101
2013 1199
2014 1388
2015 1552
2016 1700
2017 1808
2018 1755
2019 649
2020 20
Text availability
Article attribute
Article type
Publication date

Search Results

16,196 results
Results by year
Filters applied: . Clear all
Page 1
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L, et al. Ann Oncol 2018 - Clinical Trial. PMID 29145561 Free PMC article.
Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. PATIENTS AND METHODS: Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. ...Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome. CONCLUSIONS: Taken together, our study provides further support that CD73 expression is associated with a poor prognosis and reduced anti-tumor immunity in human TNBC and that targeting CD73 could be a promising strategy to reprogram the tumor microenvironment in this BC subtype....
Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. PATIENTS AND METHOD …
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
Govindan R, et al. J Clin Oncol 2017 - Clinical Trial. PMID 28854067
This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC. ...
This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus p …
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial.
Strosberg J, et al. J Clin Oncol 2018 - Clinical Trial. PMID 29878866 Free PMC article.
Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with (177)Lu-Dotatate versus high-dose octreotide. ...Conclusion This analysis from the NETTER-1 phase III study demonstrates that, in addition to improving progression-free survival, (177)Lu-Dotatate provides a significant QoL benefit for patients with progressive midgut NETs compared with high-dose octreotide....
Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly ass …
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC, et al. Clin Cancer Res 2016 - Clinical Trial. PMID 26927662 Free article.
EXPERIMENTAL DESIGN: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. ...
EXPERIMENTAL DESIGN: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized …
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
Hamstra DA, et al. Int J Radiat Oncol Biol Phys 2017 - Clinical Trial. PMID 28209443 Free article.
PURPOSE: SpaceOAR, a Food and Drug Administration-approved hydrogel intended to create a rectal-prostate space, was evaluated in a single-blind phase III trial of image guided intensity modulated radiation therapy. ...
PURPOSE: SpaceOAR, a Food and Drug Administration-approved hydrogel intended to create a rectal-prostate space, was evaluated in a single-bl …
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M, et al. Leukemia 2018 - Clinical Trial. PMID 29925908
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase (CML-CP), N = 3 accelerated phase (CML-AP), N = 7 blastic phase (CML-BP)) received imatinib up-front (300, 400, 500 mg/m(2), respectively) within a prospective phase III trial. ...This large pediatric trial extends and confirms data from smaller series that first-line imatinib in children is highly effective....
A total of 156 patients (age range 1.3-18.0 years, median 13.2 years; 91 (58.3%) male) with newly diagnosed CML (N = 146 chronic phase
Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting.
Nademanee A, et al. Biol Blood Marrow Transplant 2018 - Clinical Trial. PMID 29859255 Free article.
The phase III AETHERA trial demonstrated the efficacy of brentuximab vedotin (BV) as consolidation therapy in patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression after autologous hematopoietic stem cell transplantation (auto-HSCT; hazard ratio, .57; P < .001). ...AEs of clinical importance occurring in patients who participated in AETHERA (BV + best supportive care [BSC], n = 165; placebo + BSC, n = 164) were evaluated for time to onset, manageability through dose modification, and resolution. ...
The phase III AETHERA trial demonstrated the efficacy of brentuximab vedotin (BV) as consolidation therapy in patients …
Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?
Phan C, et al. Paediatr Drugs 2019 - Clinical Trial. PMID 31155692
BACKGROUND: Phase III clinical trials of biotherapies for childhood psoriasis are designed for a selected population, which can differ from real-life patients. ...Efficacy and safety results from phase III clinical trials in selected populations may not sufficiently reflect what is seen in real life, thus results from real-life cohort studies are necessary....
BACKGROUND: Phase III clinical trials of biotherapies for childhood psoriasis are designed for a selected population, w …
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, et al. Haemophilia 2017 - Clinical Trial. PMID 27480904
We evaluated the haemostatic efficacy and safety of one to two administrations of MC710 in 21 joint, muscle, and subcutaneous bleeding episodes in 14 male patients, in a multi-centre, open-label, non-randomized clinical trial. ...
We evaluated the haemostatic efficacy and safety of one to two administrations of MC710 in 21 joint, muscle, and subcutaneous bleeding episo …
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Kutny MA, et al. J Clin Oncol 2017 - Clinical Trial. PMID 28767288 Free PMC article.
Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. ...
Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase
16,196 results
Jump to page
Feedback